Company Filing History:
Years Active: 2003
Title: Innovator Spotlight: Chen Chen Kan and His Contributions to Pharmaceutical Research
Introduction: Chen Chen Kan is a notable inventor based in Arcadia, California, recognized for his significant contribution to the field of pharmaceutical research with a focus on therapeutic agents. His work highlights the intersection of biochemistry and medicine, particularly in relation to human effector cell cycle checkpoint proteins.
Latest Patents: Chen Chen Kan holds a patent titled "Catalytic domain of the human effector cell cycle checkpoint protein kinase materials and methods for identification of inhibitors thereof." This invention pertains to the identification, isolation, and purification of the catalytic domain of the human effector checkpoint protein kinase (hChk1). The patent outlines the crystal structure of the hChk1 kinase domain in its active conformation, with a resolution of 1.7 Å. This detailed structure aids in the discovery and development of small molecule inhibitors, potentially serving as therapeutic options for treating hyperproliferative disorders such as HIV and cancer.
Career Highlights: Currently associated with Agouron Pharmaceuticals, Inc., Chen Chen Kan has leveraged his expertise in protein kinase research to advance our understanding of cellular mechanisms that can be targeted for drug development. His patent exemplifies his dedication to harnessing scientific innovation to combat serious health conditions.
Collaborations: Throughout his career, Chen has worked alongside talented professionals such as Ping Chen and Mark Brian Anderson. Their collaborations have contributed to a rich exchange of knowledge and ideas, driving forward the objectives of their shared research endeavors.
Conclusion: Chen Chen Kan's innovative work in the field of pharmacology is paving the way for new therapeutic strategies against challenging diseases. His patent on hChk1 illustrates the critical role of inventors in transforming scientific discoveries into practical applications that can significantly impact public health.